Metronomic administration of chlorambucil for treatment of dogs with urinary bladder transitional cell carcinoma

Journal of the American Veterinary Medical Association

Volumn 242, Issue 11, 2013, Pages 1534-1538

  Schrempp, Diane R ^a,d   Childress, Michael O ^a   Stewart, Jane C ^a   Leach, Tiffany N ^a,f   Tan, Kean Ming ^b,e   Abbo, Andrew H ^a,g   de Gortari, Amalia E ^a   Bonney, Patty L ^a   Knapp, Deborah W ^a,c  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c Purdue University   (United States)

^d Veterinary Centers of America   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f Veterinary Specialty Center   (United States)

^g New England Veterinary Oncology Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHLORAMBUCIL;

ANIMAL; ANIMAL DISEASE; ARTICLE; BLADDER TUMOR; CLINICAL TRIAL; DOG; DOG DISEASE; DRUG ADMINISTRATION; FEMALE; MALE; TRANSITIONAL CELL CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; CHLORAMBUCIL; DOG DISEASES; DOGS; DRUG ADMINISTRATION SCHEDULE; FEMALE; MALE; URINARY BLADDER NEOPLASMS;

EID: 84877932383     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: 10.2460/javma.242.11.1534     Document Type: Article

References (31)

1. Mutsaers AJ, Widmer WR, Knapp DW. Canine transitional cell carcinoma. J Vet Intern Med 2003;17:136-144.
2. Arnold EJ, Childress MO, Fourez LM, et al. Clinical trial of vinblastine in dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med 2011;25:1385-1390.
3. Henry CJ, McCaw DL, Turnquist SE, et al. Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma. Clin Cancer Res 2003;9:906-911.
4. Boria PA, Glickman NW, Schmidt BR, et al. Carboplatin and piroxicam therapy in 31 dogs with transitional cell carcinoma of the urinary bladder. Vet Comp Oncol 2005;3:73-80.
5. Abbo AH, Jones DR, Masters AR, et al. Phase I clinical trial and pharmacokinetics of intravesical mitomycin C in dogs with localized transitional cell carcinoma of the urinary bladder. J Vet Intern Med 2010;24:1124-1130.
6. Greene SN, Lucroy MD, Greenberg CB, et al. Evaluation of cisplatin administered with piroxicam in dogs with transitional cell carcinoma of the urinary bladder. J Am Vet Med Assoc 2007;231:1056-1060.
7. Browder T, Butterfield CE, Kräling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-1886.
8. Rozados VR, Sánchez AM, Gervasoni SI, et al. Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity. Ann Oncol 2004;15:1543-1550.
9. Colleoni M, Rocca A, Sandri MT, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002;13:73-80.
10. Mutsaers AJ. Metronomic chemotherapy. Top Companion Anim Med 2009;24:137-143.
11. Lana S, U'Ren L, Plaza S, et al. Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. J Vet Intern Med 2007;21:764-769.
12. Elmslie RE, Glawe P, Dow SW. Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcomas. J Vet Intern Med 2008;22:1373-1379.
13. Leach TN, Childress MO, Greene SN, et al. Prospective trial of metronomic chlorambucil chemotherapy in dogs with naturally occurring cancer. Vet Comp Oncol 2012;10:102-112.
14. Paku S. Current concepts of tumor-induced angiogenesis. Pathol Oncol Res 1998;4:62-75.
15. Bertolini F, Paul S, Mancuso P, et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 2003;63:4342-4346.
16. Kerbel RS. Reappraising antiangiogenic therapy for breast cancer. Breast 2011;20:S56-S60.
17. Boehm T, Folkman J, Browder T, et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997;390:404-407.
18. Tew KD, Colvin OM, Jones RB. Clinical and high-dose alkylating agents. In: Chabner BA, Longo DL, eds. Cancer chemotherapy and biotherapy: principles and practice. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2006;283-309.
19. Chun R, Garrett LD, Vail DM. Cancer chemotherapy. In: Withrow SJ, Vail DM, eds. Withrow and MacEwen's small animal clinical oncology. 4th ed. St Louis: Saunders Elsevier, 2007;163-192.
20. Leifer CE, Matus RE. Chronic lymphocytic leukemia in the dog: 22 cases (1974-1984). J Am Vet Med Assoc 1986;189:214-217.
21. Taylor F, Gear R, Hoather T, et al. Chlorambucil and prednisolone chemotherapy for dogs with inoperable mast cell tumours: 21 cases. J Small Anim Pract 2009;50:284-289.
22. Simon RM. Design & analysis of clinical trials Phase II clinical trials. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: principles & practice of oncology. 7th ed. Philadelphia: Lippincott Williams & Wilkins, 2005;471-489.
23. Knapp DW. Tumors of the urinary system. In: Withrow SJ, Vail DM, Page RL, eds. Withrow and MacEwen's small animal clinical oncology. 5th ed. St Louis: Saunders Elsevier, 2013;572-582.
24. Schmidt LH, Fradkin R, Sullivan R, et al. Comparative pharmacology of alkylating agents. I. Cancer Chemother Rep 1965;18(suppl 2):1-401.
25. Veterinary Co-operative Oncology Group. Veterinary Co-operative Oncology Group-common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol 2004;2:195-213.
26. Chun R, Knapp DW, Widmer WR, et al. Phase II clinical trial of carboplatin in canine transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1997;11:279-283.
27. Owens L. TNM classification of tumors in domestic animals. Geneva: World Health Organization, 1980.
28. Knapp DW, Richardson RC, Chan TCK, et al. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1994;8:273-278.
29. McMillan SK, Boria P, Moore GE, et al. Antitumor effects of deracoxib treatment in 26 dogs with transitional cell carcinoma of the urinary bladder. J Am Vet Med Assoc 2011;239:1084-1089.
30. Lascelles BDX. Supportive care for the cancer patient: section A. Management of chronic cancer pain. In: Withrow SK, Vail DM, eds. Withrow and MacEwen's small animal clinical oncology. 4th ed. St Louis: Saunders Elsevier, 2007;291-306.
31. Cox CA, Amaral J, Salloum R, et al. Doxycycline's effect on ocular angiogenesis: an in vivo analysis. Ophthalmology 2010;117:1782-1791.